Lokesh Chandra
Cardiovascular Disease · Hazel Crest, ILNPI 1942363254
Payments from drug & device makers
Across 1,066 payments — averaging $2545.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1.5M
- Astrazeneca UK Limited$495K
- Novo Nordisk AS$195K
- Amgen$171K
- Boehringer Ingelheim$112K
- Merck$84K
- plus $122K from 30 others
What the payments were for
- Consulting fees$130%
- Speaking & faculty fees$3,75045%
- Food & beverage$4,54754%
- Education$921%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 43 | $1,532,343 |
| Astrazeneca UK Limited | 2 | $495,230 |
| Novo Nordisk AS | 729 | $195,292 |
| Amgen | 37 | $171,002 |
| Boehringer Ingelheim | 6 | $112,289 |
| Merck | 16 | $84,443 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 68 | $41,159 |
| Pfizer | 16 | $38,192 |
| Novartis | 51 | $28,788 |
| Vifor (international) Ltd. | 7 | $7,965 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 3 | $3,863 |
| Boehringer Ingelheim Canada Ltd.ltee | 6 | $588 |
| Boehringer Ingelheim France S.a.s. | 5 | $320 |
| GSK | 16 | $303 |
| Novo Nordisk | 10 | $181 |
| Lilly USA, LLC | 8 | $157 |
| Biotronik Inc. | 2 | $157 |
| Preventric Diagnostics, Inc. | 1 | $116 |
| Amarin Pharma, Inc. | 5 | $94 |
| E.r. Squibb & Sons, L.L.C. | 5 | $79 |
| Esperion Therapeutics, Inc. | 4 | $64 |
| Sunovion Pharmaceuticals Inc. | 3 | $53 |
| Vifor Pharma, Inc. | 1 | $53 |
| Sanofi-aventis U.S. LLC | 3 | $47 |
| Hikma Pharmaceuticals USA | 3 | $45 |
| Johnson & Johnson | 3 | $44 |
| AbbVie | 2 | $35 |
| Arbor Pharmaceuticals, Inc. | 3 | $35 |
| Edwards Lifesciences | 1 | $20 |
| Boston Scientific | 1 | $17 |
| Medtronic | 1 | $16 |
| Medicomp Inc | 1 | $16 |
| Bayer | 1 | $14 |
| Itamar Medical Inc | 1 | $13 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
| Bardy Diagnostics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,713,058 in reported general payments places this provider in the 95th percentile of 932 cardiovascular disease providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 14 | $3,806 |
| Metoprolol Succinate | 28 | $245 |
| Nifedipine ErNifedipine | 14 | $180 |
| Montelukast Sodium | 14 | $112 |
| Clonidine Hcl | 14 | $89 |
| Atorvastatin Calcium | 14 | $87 |
| Memantine Hcl | 15 | $86 |
| Metformin Hcl | 14 | $85 |
| Hydralazine Hcl | 14 | $62 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia | $84,443 | $3,80614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 932 cardiovascular disease providers in Illinois.
Other cardiovascular disease in Hazel Crest
- Benjamin LumicaoChicago$3.7M
- Paul CremerChicago$2.9M
- Steven LupovitchArlington Heights$2.6M
- Nitasha SarswatChicago$2M
- Alan BrownNaperville$1.5M
- Alexander AdlerPeoria$1.5M
- Clifford KavinskyMaywood$1.4M
- Sanjiv ShahChicago$1.2M
- Sandeep NathanChicago$1.1M
- Niraj VarmaMaywood$937K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.